DAWN
Day One Biopharmaceuticals, Inc.NASDAQHealthcare$21.45+0.14%ClosedMarket Cap: $2.22B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
5.03
P/S
14.01
EV/EBITDA
-19.11
DCF Value
$56.24
FCF Yield
-4.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
89.1%
Operating Margin
-80.8%
Net Margin
-67.8%
ROE
-23.4%
ROA
-21.1%
ROIC
-28.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $53.7M | 88.7% | $-27.5M | $-21.3M | $-0.21 | — |
| FY 2025 | $158.2M | 89.1% | $-127.8M | $-107.3M | $-1.04 | — |
| Q3 2025 | $39.8M | 88.7% | $-24.3M | $-19.7M | $-0.19 | — |
| Q2 2025 | $33.9M | 88.9% | $-35.0M | $-30.3M | $-0.29 | — |
| Q1 2025 | $30.8M | 90.6% | $-41.1M | $-36.0M | $-0.35 | — |
| Q4 2024 | $29.2M | 89.8% | $-65.3M | $-65.7M | $-0.70 | — |
| FY 2024 | $131.2M | 96.0% | $-217.3M | $-95.5M | $-1.02 | — |
| Q3 2024 | $93.8M | 98.3% | $29.6M | $37.0M | $0.38 | — |
| Q2 2024 | $8.2M | 91.4% | $-114.8M | $-4.4M | $-0.05 | — |
| Q1 2024 | $0.00 | -Infinity% | $-66.8M | $-62.4M | $-0.72 | — |
| Q4 2023 | $0.00 | -Infinity% | $-59.5M | $-54.5M | $-0.62 | — |
| FY 2023 | $0.00 | -Infinity% | $-206.1M | $-188.9M | $-2.37 | — |